Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Breast Neoplasms × Association × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Myelodysplastic Syndromes 2 Leukemia, Myeloid, Acute 2 Sarcoma, Kaposi 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma, B-Cell 1 Leukemia, Prolymphocytic 1 Leukemia, Plasma Cell 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia 1 Hematologic Diseases 1 Cholangiocarcinoma 1 Burkitt Lymphoma 1 Breast Neoplasms 1

Interventions

Trastuzumab 592 Paclitaxel 560 Cyclophosphamide 544 Docetaxel 477 Capecitabine 387 Letrozole 346 Fulvestrant 306 Doxorubicin 285 Carboplatin 277 Tamoxifen 254 Anastrozole 216 Epirubicin 210 exemestane 208 Radiotherapy 196 Bevacizumab 189 pertuzumab 172 Vinorelbine 162 Gemcitabine 162 pembrolizumab 161 Lapatinib 161 palbociclib 151 Exercise 131 Fluorouracil 118 Albumin-Bound Paclitaxel 116 eribulin 108 Magnetic Resonance Spectroscopy 108 130-nm albumin-bound paclitaxel 107 Everolimus 103 Taxes 96 Cisplatin 91

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01613482 2026-03-16

TSARINE

Centre Oscar Lambret

Phase 3 Terminated

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡